How To Use CPT Code 91308
CPT 91308 refers to the SARS-CoV-2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use. This article will cover the description, procedure, qualifying circumstances, usage, documentation requirements, billing guidelines, historical information, similar codes, and examples of CPT 91308.
1. What is CPT 91308?
CPT 91308 is a code used to represent the SARS-CoV-2 (COVID-19) vaccine product, specifically the mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, administered via intramuscular injection. This vaccine aims to reduce the patient’s risk of contracting COVID-19 by triggering an immune response against the virus.
2. 91308 CPT code description
The official description of CPT code 91308 is: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use.
3. Procedure
- Verify the patient’s eligibility for the vaccine based on age, medical history, and other factors.
- Obtain informed consent from the patient or their guardian.
- Prepare the vaccine by reconstituting the diluent with the vaccine product.
- Select the appropriate administration site, typically the deltoid muscle of the upper arm.
- Administer the vaccine intramuscularly using a sterile needle and syringe.
- Document the vaccine administration, including the date, time, and dosage.
- Monitor the patient for any immediate adverse reactions or side effects.
- Provide the patient with information on potential side effects and when to seek medical attention.
- Schedule the patient for their second dose, if applicable.
- Report the vaccine administration to the appropriate public health authorities.
4. Qualifying circumstances
Patients eligible to receive CPT code 91308 services include those who meet the age and health requirements established by the vaccine manufacturer and public health authorities. This may include individuals with certain underlying health conditions, essential workers, and those in specific age groups. Providers should consult the most recent guidelines and recommendations from public health authorities and the vaccine manufacturer to determine eligibility.
5. When to use CPT code 91308
It is appropriate to bill the 91308 CPT code when administering the SARS-CoV-2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use to eligible patients. This code should be used in conjunction with the appropriate administration codes, such as 0081A for the first dose and 0082A for the second dose.
6. Documentation requirements
To support a claim for CPT 91308, providers must document the following information:
- Patient’s demographic information, including age and medical history
- Eligibility criteria for receiving the vaccine
- Informed consent obtained from the patient or their guardian
- Vaccine product information, including manufacturer, lot number, and expiration date
- Date, time, and dosage of the vaccine administration
- Site of administration and injection technique
- Any observed adverse reactions or side effects
- Follow-up instructions provided to the patient
- Scheduled date for the second dose, if applicable
7. Billing guidelines
When billing for CPT code 91308, providers should follow the most current guidelines and rules established by payers, public health authorities, and the vaccine manufacturer. This may include using the appropriate administration codes (e.g., 0081A for the first dose and 0082A for the second dose) and not reporting 91308 in conjunction with certain other administration codes. Providers should also ensure that all required documentation is complete and accurate to support the claim.
8. Historical information
CPT 91308 was added to the Current Procedural Terminology system on June 17, 2022. There have been no updates to this code since its addition.
9. Similar codes to CPT 91308
Five similar codes to CPT 91308 and how they differentiate are:
- CPT 91300: Pfizer-BioNTech COVID-19 vaccine, which has a different dosage and formulation.
- CPT 91301: Moderna COVID-19 vaccine, which uses a different mRNA-LNP technology and dosage.
- CPT 91302: Janssen (Johnson & Johnson) COVID-19 vaccine, which is an adenovirus vector-based vaccine with a different dosage and formulation.
- CPT 91303: AstraZeneca COVID-19 vaccine, which is also an adenovirus vector-based vaccine with a different dosage and formulation.
- CPT 91304: Novavax COVID-19 vaccine, which is a protein subunit vaccine with a different dosage and formulation.
10. Examples
Here are 10 detailed examples of CPT code 91308 procedures:
CPT 91308 refers to the SARS-CoV-2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use. This article will cover the description, procedure, qualifying circumstances, usage, documentation requirements, billing guidelines, historical information, similar codes, and examples of CPT 91308.
1. What is CPT 91308?
CPT 91308 is a code used to represent the SARS-CoV-2 (COVID-19) vaccine product, specifically the mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, administered via intramuscular injection. This vaccine aims to reduce the patient’s risk of contracting COVID-19 by triggering an immune response against the virus.
2. 91308 CPT code description
The official description of CPT code 91308 is: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use.
3. Procedure
- Verify the patient’s eligibility for the vaccine based on age, medical history, and other factors.
- Obtain informed consent from the patient or their guardian.
- Prepare the vaccine by reconstituting the diluent with the vaccine product.
- Select the appropriate administration site, typically the deltoid muscle of the upper arm.
- Administer the vaccine intramuscularly using a sterile needle and syringe.
- Document the vaccine administration, including the date, time, and dosage.
- Monitor the patient for any immediate adverse reactions or side effects.
- Provide the patient with information on potential side effects and when to seek medical attention.
- Schedule the patient for their second dose, if applicable.
- Report the vaccine administration to the appropriate public health authorities.
4. Qualifying circumstances
Patients eligible to receive CPT code 91308 services include those who meet the age and health requirements established by the vaccine manufacturer and public health authorities. This may include individuals with certain underlying health conditions, essential workers, and those in specific age groups. Providers should consult the most recent guidelines and recommendations from public health authorities and the vaccine manufacturer to determine eligibility.
5. When to use CPT code 91308
It is appropriate to bill the 91308 CPT code when administering the SARS-CoV-2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use to eligible patients. This code should be used in conjunction with the appropriate administration codes, such as 0081A for the first dose and 0082A for the second dose.
6. Documentation requirements
To support a claim for CPT 91308, providers must document the following information:
- Patient’s demographic information, including age and medical history
- Eligibility criteria for receiving the vaccine
- Informed consent obtained from the patient or their guardian
- Vaccine product information, including manufacturer, lot number, and expiration date
- Date, time, and dosage of the vaccine administration
- Site of administration and injection technique
- Any observed adverse reactions or side effects
- Follow-up instructions provided to the patient
- Scheduled date for the second dose, if applicable
7. Billing guidelines
When billing for CPT code 91308, providers should follow the most current guidelines and rules established by payers, public health authorities, and the vaccine manufacturer. This may include using the appropriate administration codes (e.g., 0081A for the first dose and 0082A for the second dose) and not reporting 91308 in conjunction with certain other administration codes. Providers should also ensure that all required documentation is complete and accurate to support the claim.
8. Historical information
CPT 91308 was added to the Current Procedural Terminology system on June 17, 2022. There have been no updates to this code since its addition.
9. Similar codes to CPT 91308
Five similar codes to CPT 91308 and how they differentiate are:
- CPT 91300: Pfizer-BioNTech COVID-19 vaccine, which has a different dosage and formulation.
- CPT 91301: Moderna COVID-19 vaccine, which uses a different mRNA-LNP technology and dosage.
- CPT 91302: Janssen (Johnson & Johnson) COVID-19 vaccine, which is an adenovirus vector-based vaccine with a different dosage and formulation.
- CPT 91303: AstraZeneca COVID-19 vaccine, which is also an adenovirus vector-based vaccine with a different dosage and formulation.
- CPT 91304: Novavax COVID-19 vaccine, which is a protein subunit vaccine with a different dosage and formulation.
10. Examples
Here are 10 detailed examples of CPT code 91308 procedures:
- A 12-year-old patient with asthma receives their first dose of the CPT 91308 vaccine.
- A healthcare worker receives their second dose of the CPT 91308 vaccine as part of an occupational vaccination program.
- An elderly patient in a long-term care facility receives their first dose of the CPT 91308 vaccine.
- A pregnant patient receives their first dose of the CPT 91308 vaccine after consulting with their healthcare provider.
- A patient with a history of severe allergic reactions to vaccines receives the CPT 91308 vaccine under close medical supervision.
- A college student receives their second dose of the CPT 91308 vaccine before returning to campus.
- A patient with a compromised immune system receives their first dose of the CPT 91308 vaccine after discussing the risks and benefits with their healthcare provider.
- An essential worker receives their second dose of the CPT 91308 vaccine at a community vaccination clinic.
- A patient with a history of COVID-19 infection receives their first dose of the CPT 91308 vaccine after recovering from the illness.
- A patient who previously received a different COVID-19 vaccine receives the CPT 91308 vaccine as part of a clinical trial evaluating the safety and efficacy of mixed vaccine schedules.
